| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/29/2004 | US20040018172 Interferon alpha hybrids |
| 01/29/2004 | US20040018171 Biochemical conjugates comprising tumor necrosis factor or interferons and ligands of CD antigen receptors, used as anticarcinogenic agents |
| 01/29/2004 | US20040018170 Chimeric proteins comprising death domains fused to biotin-streptavidin binding pairs, administered for prophylaxis of asthma, allergies, poisoning, autoimmune or graft versus host disease |
| 01/29/2004 | US20040018169 Method for reducing oxalate |
| 01/29/2004 | US20040018157 Oral composition providing enhanced oral hygiene properties |
| 01/29/2004 | DE10229379A1 EG-VEGF Rezeptor Antagonisten EG-VEGF receptor antagonists |
| 01/29/2004 | DE10229180A1 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen Use of vasopeptidase inhibitors for the treatment of metabolic disorders, nephropathy, and diseases associated with AGE |
| 01/29/2004 | DE10227136A1 Thiazolidindione enthaltende Zusammensetzungen und deren Verwendung Thiazolidinediones compositions containing them and their use |
| 01/29/2004 | CA2496912A1 Methods and compositions for treating diabetes mellitis |
| 01/29/2004 | CA2496253A1 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 01/29/2004 | CA2493572A1 Methods and compositions for activating or inhibiting vegf-d and vegf-c |
| 01/29/2004 | CA2493499A1 Compositions and methods for sirna inhibition of angiogenesis |
| 01/29/2004 | CA2493341A1 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 01/29/2004 | CA2493232A1 Antisense compounds, methods and compositions for treating mmp-12 related inflammatory disorders |
| 01/29/2004 | CA2493064A1 Tumor treating combinations, compositions and methods |
| 01/29/2004 | CA2493007A1 Protein complexes of the tip60 transcriptional activator protein |
| 01/29/2004 | CA2492806A1 Targeted agents for nerve regeneration |
| 01/29/2004 | CA2492598A1 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 01/29/2004 | CA2492472A1 Use of urease for inhibiting cancer cell growth |
| 01/29/2004 | CA2492331A1 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 01/29/2004 | CA2492225A1 Combination therapy for the treatment of obesity |
| 01/29/2004 | CA2491946A1 Ghrelin analogs |
| 01/29/2004 | CA2489008A1 Ghrelin-carrier conjugates |
| 01/29/2004 | CA2467691A1 Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections |
| 01/28/2004 | EP1384783A1 Novel maxizyme |
| 01/28/2004 | EP1384781A1 Methods for Modulating T-Cell Survival by Modulating BCL-XL Protein Level |
| 01/28/2004 | EP1384774A1 Glycosaminoglycan/collagen complexes and use thereof |
| 01/28/2004 | EP1384725A2 Factor Xa inhibitors |
| 01/28/2004 | EP1384710A1 Synthesis of heterocyclic compounds containing five- or six-membered rings |
| 01/28/2004 | EP1384486A1 Use of p43 for stimulating wound healing |
| 01/28/2004 | EP1384485A1 Bactericidal/permeability increasing protein or biologically active analogs thereof to treat lipopolysaccharide associated gram negative infections |
| 01/28/2004 | EP1384484A1 Use of efrapeptin oligopeptides for inhibition of angiogenesis |
| 01/28/2004 | EP1384081A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs |
| 01/28/2004 | EP1383929A2 Genes expressed in intestinal epithelium and peyer's patch m cells |
| 01/28/2004 | EP1383927A2 New polynucleotides and polypeptides of the erythropoietin gene |
| 01/28/2004 | EP1383922A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 01/28/2004 | EP1383897A2 Self-containing lactococcus strain |
| 01/28/2004 | EP1383895A2 Polynucleotides and polypeptides of the ifnalpha-5 gene |
| 01/28/2004 | EP1383893A2 Proteins and nucleic acids encoding same |
| 01/28/2004 | EP1383892A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/28/2004 | EP1383888A2 Human secreted proteins |
| 01/28/2004 | EP1383885A1 Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof |
| 01/28/2004 | EP1383883A2 Asthma-associated snps around microsatellite marker d2s308 and identification of human prolyl-oligopeptidase-dpp10 |
| 01/28/2004 | EP1383880A1 Novel human kinase and polynucleotides encoding the same |
| 01/28/2004 | EP1383878A2 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof |
| 01/28/2004 | EP1383876A1 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof |
| 01/28/2004 | EP1383801A1 Antibodies against cancer |
| 01/28/2004 | EP1383798A2 Transporters and ion channels |
| 01/28/2004 | EP1383794A2 Daptomycin and related analogs in crystalline form, thier preparation and use |
| 01/28/2004 | EP1383793A2 Insulin and igf-1 receptor agonists and antagonists |
| 01/28/2004 | EP1383792A2 Sh2 domain binding inhibitors |
| 01/28/2004 | EP1383789A2 Proteins associated with cell growth, differentiation, and death |
| 01/28/2004 | EP1383785A2 Recombinant tumor specific antibody and use thereof |
| 01/28/2004 | EP1383782A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| 01/28/2004 | EP1383778A2 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 01/28/2004 | EP1383733A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
| 01/28/2004 | EP1383731A1 Biaryl compounds as serine protease inhibitors |
| 01/28/2004 | EP1383578A1 Single dose aromatase inhibitor for treating infertility |
| 01/28/2004 | EP1383544A1 Anti-cd19 immunotoxins |
| 01/28/2004 | EP1383541A1 Methods for delivering nucleic acid molecules into cells and assessment thereof |
| 01/28/2004 | EP1383540A2 Methods and pharmaceutical compositions for healing wounds |
| 01/28/2004 | EP1383536A1 Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit ccr5-tropic hiv-1 infection and replication |
| 01/28/2004 | EP1383531A2 Use of lp82 to treat hematopoietic disorders |
| 01/28/2004 | EP1383530A2 Laminin 5, 13 and 14 and uses thereof |
| 01/28/2004 | EP1383529A2 Methods of treating disorders of the eye and surrounding tissue with thymosin 4 (t 4), analogues, isoforms and other derivatives |
| 01/28/2004 | EP1383528A2 Epitope sequences |
| 01/28/2004 | EP1383527A1 Methods and compositions for treating oral and esophageal lesions |
| 01/28/2004 | EP1383526A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 01/28/2004 | EP1383518A1 Oral delivery of macromolecules |
| 01/28/2004 | EP1383513A1 Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors |
| 01/28/2004 | EP1383509A1 A drug for use in bone grafting |
| 01/28/2004 | EP1383502A2 Compounds and methods for the treatment of urogenital disorders |
| 01/28/2004 | EP1383492A1 Molecular conjugates for use in treatment of cancer |
| 01/28/2004 | EP1383491A2 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
| 01/28/2004 | EP1383490A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 01/28/2004 | EP1383481A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 01/28/2004 | EP1383460A2 Crf 2? ligands in combination therapy |
| 01/28/2004 | EP1383380A2 Fizz1 for metabolism regulation |
| 01/28/2004 | EP1383376A2 Pharmaceutical formulations for sustained release |
| 01/28/2004 | EP1296676B1 Use of indole-3-acetic acid derivatives in medicine |
| 01/28/2004 | EP1217990B1 Cationic dosper virosomes |
| 01/28/2004 | EP1194158B1 The use of the protein uk 114 for inhibiting organ transplant rejection |
| 01/28/2004 | EP1165102B1 Matrix protein compositions for grafting in non-mineralised tissue |
| 01/28/2004 | EP1089718B1 Sticking plaster for controlled release of natural interferon |
| 01/28/2004 | EP1061944B1 Therapeutic chemokine receptor antagonists |
| 01/28/2004 | EP0968291B1 Antibody fragment-polymer conjugates |
| 01/28/2004 | EP0914345B1 Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
| 01/28/2004 | EP0724597B1 Ks-laminin and methods of use |
| 01/28/2004 | EP0690675B1 Nucleic acid coding for a tumor rejection antigen precursor |
| 01/28/2004 | CN1471583A Packaging of positive-strand RNA virus replicon particles |
| 01/28/2004 | CN1471579A CRIPTO tumour polypeptide |
| 01/28/2004 | CN1471539A Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies |
| 01/28/2004 | CN1471538A Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| 01/28/2004 | CN1471528A Pyrrolidine derivatives and their use as chymase inhibitor |
| 01/28/2004 | CN1471526A Dioxolane analogs for improved inter-cellular delivery |
| 01/28/2004 | CN1471408A Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers |
| 01/28/2004 | CN1471407A Multifunctional nano device platform |
| 01/28/2004 | CN1471405A Suspension of an EPI-HNE protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical composition containing said suspension or aerosol, and their uses |
| 01/28/2004 | CN1471404A Antiparkinsonism drugs |
| 01/28/2004 | CN1471393A Method for the treatment of neurological and neuropsychological disorders |